Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection
The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional...
Gespeichert in:
| Veröffentlicht in: | Annual review of clinical psychology 2013-01, Vol.9 (1), p.621-648 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 648 |
|---|---|
| container_issue | 1 |
| container_start_page | 621 |
| container_title | Annual review of clinical psychology |
| container_volume | 9 |
| creator | Risacher, Shannon L Saykin, Andrew J |
| description | The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Next, we evaluate findings from these biomarkers in preclinical and prodromal stages of AD including mild cognitive impairment (MCI) and pre-MCI conditions conferring elevated risk. We then discuss related findings in patients with dominantly inherited AD. We conclude with a discussion of the current theoretical framework for the role of biomarkers in AD and emergent directions for AD biomarker research. |
| doi_str_mv | 10.1146/annurev-clinpsy-050212-185535 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3955298</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1321793468</sourcerecordid><originalsourceid>FETCH-LOGICAL-a593t-f9b156cca756d40e38457a961a94a0244975964c8faf24e1d07b21903c7f28073</originalsourceid><addsrcrecordid>eNqVkc1u1DAURiMEoqXwCsgbRDdp_ZvESCC101KQRnRT1tYd52ZiSOzBTloNT98MGUawQqxsyd93fK9Olr1h9IwxWZyD92PE-9x2zm_SNqeKcsZzVikl1JPsmClZ5Uor9vRwl-Ioe5HSN0qFkIo_z4644LosK3Wc1V9wjMH1sHZ-TcDX5HZoMZJLF3qI3zEm0oRILrqfLboe49tErlxCSPiO3LVIFi34X9Xl1E0WNkhCQ64hdltyhQPawQX_MnvWQJfw1f48yb5-vL5bfMqXtzefFxfLHJQWQ97oFVOFtVCqopYURSVVCbpgoCVQLqUulS6krRpouERW03LFmabClg2vaClOsg8zdzOueqwt-iFCZzZx2i9uTQBn_n7xrjXrcG-EVorragKc7gEx_BgxDaZ3yWLXgccwJsMk06Jgpeb_jgo-5YQsdtT3c9TGkFLE5jARo2Yn1eylmr1UM0s1s9Sp__rPtQ7t3xanwOUc2HGgm0gOH9J__vIIsWO6mg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1321793468</pqid></control><display><type>article</type><title>Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection</title><source>Annual Reviews Complete A-Z List</source><source>MEDLINE</source><creator>Risacher, Shannon L ; Saykin, Andrew J</creator><creatorcontrib>Risacher, Shannon L ; Saykin, Andrew J</creatorcontrib><description>The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Next, we evaluate findings from these biomarkers in preclinical and prodromal stages of AD including mild cognitive impairment (MCI) and pre-MCI conditions conferring elevated risk. We then discuss related findings in patients with dominantly inherited AD. We conclude with a discussion of the current theoretical framework for the role of biomarkers in AD and emergent directions for AD biomarker research.</description><identifier>ISSN: 1548-5943</identifier><identifier>EISSN: 1548-5951</identifier><identifier>DOI: 10.1146/annurev-clinpsy-050212-185535</identifier><identifier>PMID: 23297785</identifier><language>eng</language><publisher>United States: Annual Reviews</publisher><subject>Alzheimer Disease - cerebrospinal fluid ; Alzheimer Disease - diagnosis ; Alzheimer Disease - pathology ; Biomarkers - cerebrospinal fluid ; cerebrospinal fluid (CSF) ; Cognitive Dysfunction - cerebrospinal fluid ; Cognitive Dysfunction - diagnosis ; Cognitive Dysfunction - pathology ; Early Diagnosis ; functional MRI (fMRI) ; genetics ; Humans ; magnetic resonance imaging (MRI) ; Magnetic Resonance Imaging - methods ; mild cognitive impairment (MCI) ; Neuroimaging - methods ; positron emission tomography (PET) ; Positron-Emission Tomography - methods ; preclinical Alzheimer's disease (AD) ; Prodromal Symptoms</subject><ispartof>Annual review of clinical psychology, 2013-01, Vol.9 (1), p.621-648</ispartof><rights>Copyright © 2013 by Annual Reviews. All rights reserved 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a593t-f9b156cca756d40e38457a961a94a0244975964c8faf24e1d07b21903c7f28073</citedby><cites>FETCH-LOGICAL-a593t-f9b156cca756d40e38457a961a94a0244975964c8faf24e1d07b21903c7f28073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.annualreviews.org/content/journals/10.1146/annurev-clinpsy-050212-185535?crawler=true&mimetype=application/pdf$$EPDF$$P50$$Gannualreviews$$H</linktopdf><linktohtml>$$Uhttps://www.annualreviews.org/content/journals/10.1146/annurev-clinpsy-050212-185535$$EHTML$$P50$$Gannualreviews$$H</linktohtml><link.rule.ids>70,230,314,776,780,881,4168,27903,27904,78000,78001</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23297785$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Risacher, Shannon L</creatorcontrib><creatorcontrib>Saykin, Andrew J</creatorcontrib><title>Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection</title><title>Annual review of clinical psychology</title><addtitle>Annu Rev Clin Psychol</addtitle><description>The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Next, we evaluate findings from these biomarkers in preclinical and prodromal stages of AD including mild cognitive impairment (MCI) and pre-MCI conditions conferring elevated risk. We then discuss related findings in patients with dominantly inherited AD. We conclude with a discussion of the current theoretical framework for the role of biomarkers in AD and emergent directions for AD biomarker research.</description><subject>Alzheimer Disease - cerebrospinal fluid</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - pathology</subject><subject>Biomarkers - cerebrospinal fluid</subject><subject>cerebrospinal fluid (CSF)</subject><subject>Cognitive Dysfunction - cerebrospinal fluid</subject><subject>Cognitive Dysfunction - diagnosis</subject><subject>Cognitive Dysfunction - pathology</subject><subject>Early Diagnosis</subject><subject>functional MRI (fMRI)</subject><subject>genetics</subject><subject>Humans</subject><subject>magnetic resonance imaging (MRI)</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>mild cognitive impairment (MCI)</subject><subject>Neuroimaging - methods</subject><subject>positron emission tomography (PET)</subject><subject>Positron-Emission Tomography - methods</subject><subject>preclinical Alzheimer's disease (AD)</subject><subject>Prodromal Symptoms</subject><issn>1548-5943</issn><issn>1548-5951</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkc1u1DAURiMEoqXwCsgbRDdp_ZvESCC101KQRnRT1tYd52ZiSOzBTloNT98MGUawQqxsyd93fK9Olr1h9IwxWZyD92PE-9x2zm_SNqeKcsZzVikl1JPsmClZ5Uor9vRwl-Ioe5HSN0qFkIo_z4644LosK3Wc1V9wjMH1sHZ-TcDX5HZoMZJLF3qI3zEm0oRILrqfLboe49tErlxCSPiO3LVIFi34X9Xl1E0WNkhCQ64hdltyhQPawQX_MnvWQJfw1f48yb5-vL5bfMqXtzefFxfLHJQWQ97oFVOFtVCqopYURSVVCbpgoCVQLqUulS6krRpouERW03LFmabClg2vaClOsg8zdzOueqwt-iFCZzZx2i9uTQBn_n7xrjXrcG-EVorragKc7gEx_BgxDaZ3yWLXgccwJsMk06Jgpeb_jgo-5YQsdtT3c9TGkFLE5jARo2Yn1eylmr1UM0s1s9Sp__rPtQ7t3xanwOUc2HGgm0gOH9J__vIIsWO6mg</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Risacher, Shannon L</creator><creator>Saykin, Andrew J</creator><general>Annual Reviews</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>20130101</creationdate><title>Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection</title><author>Risacher, Shannon L ; Saykin, Andrew J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a593t-f9b156cca756d40e38457a961a94a0244975964c8faf24e1d07b21903c7f28073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alzheimer Disease - cerebrospinal fluid</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - pathology</topic><topic>Biomarkers - cerebrospinal fluid</topic><topic>cerebrospinal fluid (CSF)</topic><topic>Cognitive Dysfunction - cerebrospinal fluid</topic><topic>Cognitive Dysfunction - diagnosis</topic><topic>Cognitive Dysfunction - pathology</topic><topic>Early Diagnosis</topic><topic>functional MRI (fMRI)</topic><topic>genetics</topic><topic>Humans</topic><topic>magnetic resonance imaging (MRI)</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>mild cognitive impairment (MCI)</topic><topic>Neuroimaging - methods</topic><topic>positron emission tomography (PET)</topic><topic>Positron-Emission Tomography - methods</topic><topic>preclinical Alzheimer's disease (AD)</topic><topic>Prodromal Symptoms</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Risacher, Shannon L</creatorcontrib><creatorcontrib>Saykin, Andrew J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annual review of clinical psychology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Risacher, Shannon L</au><au>Saykin, Andrew J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection</atitle><jtitle>Annual review of clinical psychology</jtitle><addtitle>Annu Rev Clin Psychol</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>9</volume><issue>1</issue><spage>621</spage><epage>648</epage><pages>621-648</pages><issn>1548-5943</issn><eissn>1548-5951</eissn><abstract>The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Next, we evaluate findings from these biomarkers in preclinical and prodromal stages of AD including mild cognitive impairment (MCI) and pre-MCI conditions conferring elevated risk. We then discuss related findings in patients with dominantly inherited AD. We conclude with a discussion of the current theoretical framework for the role of biomarkers in AD and emergent directions for AD biomarker research.</abstract><cop>United States</cop><pub>Annual Reviews</pub><pmid>23297785</pmid><doi>10.1146/annurev-clinpsy-050212-185535</doi><tpages>28</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1548-5943 |
| ispartof | Annual review of clinical psychology, 2013-01, Vol.9 (1), p.621-648 |
| issn | 1548-5943 1548-5951 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3955298 |
| source | Annual Reviews Complete A-Z List; MEDLINE |
| subjects | Alzheimer Disease - cerebrospinal fluid Alzheimer Disease - diagnosis Alzheimer Disease - pathology Biomarkers - cerebrospinal fluid cerebrospinal fluid (CSF) Cognitive Dysfunction - cerebrospinal fluid Cognitive Dysfunction - diagnosis Cognitive Dysfunction - pathology Early Diagnosis functional MRI (fMRI) genetics Humans magnetic resonance imaging (MRI) Magnetic Resonance Imaging - methods mild cognitive impairment (MCI) Neuroimaging - methods positron emission tomography (PET) Positron-Emission Tomography - methods preclinical Alzheimer's disease (AD) Prodromal Symptoms |
| title | Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A25%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuroimaging%20and%20Other%20Biomarkers%20for%20Alzheimer's%20Disease:%20The%20Changing%20Landscape%20of%20Early%20Detection&rft.jtitle=Annual%20review%20of%20clinical%20psychology&rft.au=Risacher,%20Shannon%20L&rft.date=2013-01-01&rft.volume=9&rft.issue=1&rft.spage=621&rft.epage=648&rft.pages=621-648&rft.issn=1548-5943&rft.eissn=1548-5951&rft_id=info:doi/10.1146/annurev-clinpsy-050212-185535&rft_dat=%3Cproquest_pubme%3E1321793468%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1321793468&rft_id=info:pmid/23297785&rfr_iscdi=true |